Cargando…
西妥昔单抗联合化疗治疗晚期非小细胞肺癌的临床疗效分析
BACKGROUND AND OBJECTIVE: Cetuximab is a monoclonal antibody directed against epidermal growth factor receptor. Emerging evidence showed improved efficacy with the addition of cetuximab to chemotherapy in advanced non-small cell lung cancer (NSCLC), but the data in oriental population are limited. T...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973051/ https://www.ncbi.nlm.nih.gov/pubmed/27215454 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.05.03 |